Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309244 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up
A Phase 3 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 677
- Enrollment target
NCT00309244 is a Phase 3 study that has completed, run by Mannkind Corporation. The registered enrollment target is 677 participants.
The verdict
NCT00309244, a Phase 3 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 677 participants
- Enrollment target
Study Summary
The purpose of this 13 month study (12 month treatment period and 1 month follow-up period) is to determine whether inhaled insulin is safe and effective in the treatment of type 2 diabetes.
Interventions
- DRUG Technosphere® Insulin Inhalation Powder
- DRUG 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 677 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00309244
The ClinicalTrials.gov registry entry for NCT00309244 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 677 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Technosphere® Insulin Inhalation Powder is the first listed.
NCT00309244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00309244 about?
NCT00309244 is a clinical study titled "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up". The purpose of this 13 month study (12 month treatment period and 1 month follow-up period) is to determine whether inhaled insulin is safe and effective in the treatment of type 2 diabetes.
What is the current status of trial NCT00309244?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 677 participants. The study started on 2006-02. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00309244?
The interventions under investigation include: Technosphere® Insulin Inhalation Powder (DRUG), 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) (DRUG).
Who is sponsoring clinical trial NCT00309244?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.